MESA LABORATORIES INC /CO/ 8-K

What Happened

• Mesa Laboratories, Inc. (MLAB) announced that Gary Owens will depart as President and Chief Executive Officer, effective on or about April 13, 2026.
• On March 20, 2026, the company and Owens entered a Retention and Transition Agreement under which he will remain in a non‑executive role to facilitate the handover through a Separation Date of June 22, 2026. Owens also resigned from the company’s board of directors effective March 20, 2026.
• The company filed the Transition Agreement as Exhibit 10.1 to the Form 8-K.

Key Details

• CEO departure announced March 9, 2026; effective as CEO on or about April 13, 2026.
• Transition Agreement dated March 20, 2026: Owens will stay with the company in a non‑executive capacity until June 22, 2026 (Separation Date).
• Upon termination on the Separation Date, Owens is entitled to severance pay and benefits equivalent to a “without cause” termination and to retain a pro‑rated portion of his June 15, 2025 performance stock unit award (vesting at the lower of target or actual performance).
• Receipt of severance and benefits is conditioned on Owens executing a release of claims. His board resignation was not due to any disagreement with the company.

Why It Matters

• A CEO transition is a material leadership change that can affect company strategy, investor confidence, and short‑term management continuity; the planned transition through June 22 aims to provide continuity.
• The Transition Agreement may result in near‑term compensation expense (severance and pro‑rated equity vesting) and creates a clear timetable for management change.
• Investors should watch for announcement of Owens’ successor, any changes to strategic direction or guidance, and disclosure of the financial impact of the separation in future filings.